ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

General Practice

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,084Medicare Part D Prescriptions Filled, Including Refills

Rank: 10 out of 55

$428K Total Retail Price of All Prescriptions

Rank: 15 out of 55

414 Patients Receiving at Least One Drug in Part D
76%Patients 65 Years and Older
83% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Oklahoma
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 414 patients filled at least one prescription for a schedule two drug, compared to an average of 9%.

Schedule Three
Controlled Substances

26% of this provider’s 414 patients filled at least one prescription for a schedule three drug, compared to an average of 21%.

Risky Drugs to Seniors

2% of this provider’s 7,867 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

27% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$47 was the average price of a prescription from this provider, compared to $57 among peers.

Prescriptions per Patient

22 is the average number of prescriptions (including refills) per patient, compared to an average of 19.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Oklahoma
FUROSEMIDE 377 359 1 5
LISINOPRIL 307 252 2 2
LEVOTHYROXINE SODIUM 288 273 3 3
POTASSIUM CHLORIDE 266 248 4 7
HYDROCODONE-ACETAMINOPHEN 240 194 S3 5 1
MELOXICAM 225 177 6 11
OMEPRAZOLE 199 166 7 4
RISPERIDONE 186 169 8 49
METFORMIN HCL 182 156 9 8
DONEPEZIL HCL 175 166 10 24
NAMENDA 167 147 11 23
SIMVASTATIN 158 149 12 6
METOPROLOL SUCCINATE 154 129 13 18
HYDROCHLOROTHIAZIDE 150 128 14 15
AMLODIPINE BESYLATE 147 140 15 9
METOPROLOL TARTRATE 138 127 16 14
SERTRALINE HCL 131 118 17 22
NEXIUM 130 103 18 20
POLYETHYLENE GLYCOL 3350 116 110 19 33
DIGOXIN 89 89 20 43
TRAMADOL HCL 87 60 21 13
WARFARIN SODIUM 87 71 21 21
CLOPIDOGREL 86 86 23 30
CIPROFLOXACIN HCL 86 72 23 32
SULFAMETHOXAZOLE-TRIMETHOPRIM 83 72 25 70
CYCLOBENZAPRINE HCL 82 62 R 26 34
SPIRONOLACTONE 80 74 27 71
ISOSORBIDE MONONITRATE ER 77 77 28 92
TRAZODONE HCL 77 74 28 39
PROAIR HFA 74 66 30 50
CARBIDOPA-LEVODOPA 73 63 31 69
GLIMEPIRIDE 68 68 32 78
ZOLPIDEM TARTRATE 67 42 33 17
MIRTAZAPINE 66 49 34 66
ATENOLOL 64 49 35 27
PREDNISONE 64 60 35 77
ETODOLAC 62 54 37 116
GABAPENTIN 61 47 38 10
AZITHROMYCIN 59 51 39 36
LANTUS 59 48 39 37
RANITIDINE HCL 55 44 41 29
FENTANYL 53 43 S2 42 61
ESCITALOPRAM OXALATE 53 44 42 86
DIVALPROEX SODIUM ER 53 47 42 88
DIVALPROEX SODIUM 51 30 45 106
CLONIDINE HCL 51 44 45 38
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on April 17, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.